Akeso's Cadonilimab Gets NMPA Approval For First-line Cervical Cancer Treatment
5/6 03:49
(RTTNews) - Akeso Inc. announced that the National Medical Products Administration (NMPA) has approved the company's first- in-class PD-1/CTLA-4 bispecific antibody, cadonilimab, for the first-line treatment of persistent, recurrent, or metastatic cervical cancer, in combination...